United Therapeutics Corporation
General ticker "UTHR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $22.2B (TTM average)
United Therapeutics Corporation follows the US Stock Market performance with the rate: 21.7%.
Estimated limits based on current volatility of 1.4%: low 532.39$, high 546.74$
Factors to consider:
- Total employees count: 1400 (+7.3%) as of 2025
- US accounted for 35.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Sales concentration risk, Regulatory and compliance, Supply chain disruptions, Key person dependency, Third-party risks
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [371.32$, 519.52$]
- 2026-12-31 to 2027-12-31 estimated range: [386.45$, 538.79$]
Financial Metrics affecting the UTHR estimates:
- Negative: with PPE of 18.1 at the end of fiscal year the price was high
- Positive: 6.77 < Operating cash flow per share per price, % of 6.98
- Positive: Operating profit margin, % of 46.89 > 33.79
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.48 > 10.70
- Positive: Interest expense per share per price, % of 0.09 <= 0.33
- Positive: -2.60 < Investing cash flow per share per price, % of -2.47
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 90.05 > 81.92
Short-term UTHR quotes
Long-term UTHR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,327.50MM | $2,877.40MM | $3,182.70MM |
| Operating Expenses | $1,142.60MM | $1,500.40MM | $1,690.20MM |
| Operating Income | $1,184.90MM | $1,377.00MM | $1,492.50MM |
| Non-Operating Income | $89.40MM | $162.00MM | $221.40MM |
| Interest Expense | $59.30MM | $42.90MM | $19.50MM |
| R&D Expense | $408.00MM | $481.00MM | $550.00MM |
| Income(Loss) | $1,274.30MM | $1,539.00MM | $1,713.90MM |
| Taxes | $289.50MM | $343.90MM | $379.20MM |
| Net Income(Loss)* | $984.80MM | $1,195.10MM | $1,334.70MM |
| Stockholders Equity | $5,984.80MM | $6,444.00MM | $7,096.20MM |
| Inventory | $111.80MM | $157.90MM | $183.10MM |
| Assets | $7,167.00MM | $7,364.00MM | $7,880.00MM |
| Operating Cash Flow | $978.00MM | $1,327.10MM | $1,561.20MM |
| Capital expenditure | $230.40MM | $246.50MM | $520.50MM |
| Investing Cash Flow | $-719.60MM | $417.20MM | $-551.30MM |
| Financing Cash Flow | $-11.90MM | $-1,254.80MM | $-1,150.00MM |
| Earnings Per Share** | $21.04 | $26.44 | $30.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.